ERBB2 and neoplasm: 11A4-ABD-maleimide-auristatin F showed a greater anti-tumor efficacy after a single-dose administration in in vivo assay using HER2-positive NCI-N87 xenograft-bearing mice, compared to 11A4-maleimide-auristatin F without ABD [43].